Table 1 Baseline characteristics in the ARISE HF Trial
From: Characterizing diabetic cardiomyopathy: baseline results from the ARISE-HF trial
n | 691 |
Age, years, mean (SD) | 67.4 (7.2) |
Female, N (%) | 348 (50.4) |
Race, N (%) | Â |
 White, non-Hispanic | 432 (62.5) |
 Hispanic | 151 (21.9) |
 Black | 42 (6.1) |
 Asian | 56 (8.1) |
 American Indian or Alaskan Native | 4 (0.6) |
 Other | 6 (0.9) |
Body-mass index, kg/m2, mean (SD) | 30.6 (4.57) |
Smoking Status, N (%) | Â |
 Current Smoker | 64 (9.3) |
 Previous Smoker | 240 (34.7) |
 Never | 387 (56.0) |
Vital signs at screening | Â |
 Systolic blood pressure, mmHg, mean (SD) | 129 (11) |
 Diastolic blood pressure, mmHg, mean (SD) | 76 (8) |
 Heart rate, beats/minute, mean (SD) | 69 (11) |
Medical history, N (%) | Â |
 Hypertension | 523 (75.7) |
 Dyslipidemia | 117 (16.9) |
Duration of T2DM, years, mean (SD) | 14.5 (10.1) |
Concomitant medications, N (%) | Â |
 Statins | 558 (80.8) |
 Angiotensin converting enzyme inhibitor or angiotensin II receptor blocker | 519 (75.1) |
 Beta blocker | 161 (23.3) |
 Mineralocorticoid receptor antagonist | 21 (3.0) |
 Hydrochlorothiazide | 133 (19.2) |
 Sodium/glucose cotransporter 2 inhibitor | 221 (32.0) |
 Glucagon-like peptide-1 receptor agonist | 173 (25.0) |
 Metformin | 512 (74.1) |
 Insulin | 188 (27.2) |
 Sulfonylurea | 160 (23.2) |
 Dipeptidylpeptidase-4 inhibitor | 85 (12.3) |